Medical device data management is the set of engineering, architectural, and regulatory practices governing how data from medical devices is captured, transmitted, stored, converted, displayed, and integrated with other clinical systems. It spans the full data lifecycle from sensor reading to clinician dashboard, and it sits at the intersection of cloud architecture, secure transmission, regulatory compliance (HIPAA, GDPR, 21 CFR Part 11, FDA cybersecurity), and clinical workflow integration. For medical device companies, getting data management right early prevents architectural and regulatory rework later.
For startup medical device companies, the discipline matters because data management decisions compound. Early choices about where data is stored, how it’s transmitted, what formats it uses, how it’s integrated with EHRs, and what audit trails it maintains all affect downstream regulatory work — particularly when the device enters Investigational Device Exemption (IDE) submission, 510(k) preparation, or post-market surveillance. The sections below walk through what medical device data management actually entails, the regulatory frameworks that apply, and the architectural decisions that most often create downstream burden when made without considering regulatory implications.
The Five Categories of Medical Device Data
Medical device data isn’t a single type — it’s a portfolio of distinct data categories, each with its own capture mechanism, storage requirements, regulatory considerations, and integration challenges. Understanding the five categories that most medical device companies handle helps clarify what data management actually means in practice.
Category 1 — Physiological and biometric data
The core data type for most medical devices: physiological measurements captured by sensors. Continuous glucose values from CGM sensors, heart rate and ECG from cardiac monitors, blood oxygen from pulse oximeters, blood pressure from connected cuffs, weight from connected scales. This category has the highest data volume on most platforms because of high-frequency capture (CGM reads every 1-5 minutes; ECG continuously). Storage, transmission, and conversion architectures are typically designed around the volume characteristics of this category.
Category 2 — Device telemetry and operational data
Data about the device itself rather than the patient: battery levels, connectivity status, firmware versions, calibration history, sensor wear time, error states, software update logs. Critical for device reliability monitoring and required for post-market surveillance documentation. For connected devices, telemetry is often as voluminous as physiological data — and is what enables predictive maintenance, remote troubleshooting, and the field-action workflows FDA expects manufacturers to maintain.
Category 3 — User interaction and behavioral data
Data captured from the patient or clinician’s use of the device’s connected software: app session times, feature usage, alert acknowledgments, manual entries (medication doses, meal logs, symptoms), and clinical workflow actions. This category often crosses into Software as a Medical Device (SaMD) territory when the behavioral data is used to drive recommendations or analysis. It’s also the category most often subject to general consumer privacy laws beyond HIPAA — particularly state-level privacy laws and GDPR.
Category 4 — Clinical and research data
Data captured specifically for clinical investigation or research purposes — Investigational Device Exemption studies, post-approval studies, registries, real-world evidence collection. Subject to additional regulatory requirements beyond standard medical device data: 21 CFR Part 11 for electronic records and signatures; the Common Rule and ICH GCP for human subjects research; and audit trail requirements that exceed those typical of routine clinical operations. This category is where data management architecture decisions most directly affect IDE submission preparation.
Category 5 — Integration and audit data
Data that documents how the device interacts with other systems: EHR integration logs, HL7/FHIR message histories, third-party API call records, data export/import records, user authentication and access logs, and the comprehensive audit trails that demonstrate data integrity over time. Often overlooked early in development, this category is what FDA, notified bodies, and IT security auditors examine when questions arise — and reconstructing it retroactively is meaningfully harder than capturing it from the start.
The Five Regulatory Frameworks That Govern Medical Device Data
Medical device data is governed by overlapping regulatory frameworks — and the framework that applies to a given data type depends on what the data is, where it’s collected, how it’s used, and where the patient is located. The five frameworks below are the ones most startup medical device companies need to understand and design for, often simultaneously. Each has distinct requirements; none of them substitute for the others.
Framework 1 — FDA MDDS guidance (Cures Act)
Following the 21st Century Cures Act of 2016, software functions that meet the Medical Device Data System (MDDS) criteria — transfer, storage, conversion, display of medical device data without analysis — are no longer FDA-regulated as devices. This is the most consequential regulatory framework for medical device data management because it determines whether the data-handling layer of your product is subject to device regulation at all. For most startup connected device platforms, substantial portions of the data infrastructure qualify as Non-Device-MDDS and are not subject to 510(k), registration, listing, MDR, or design controls under FDA device rules.
Framework 2 — HIPAA (US data privacy and security)
HIPAA’s Privacy and Security Rules apply to medical device data when the device manufacturer is a covered entity or business associate of a covered entity. Most medical device manufacturers are business associates when they store, transmit, or process Protected Health Information (PHI) on behalf of healthcare providers. HIPAA requires administrative, physical, and technical safeguards: access controls, audit logs, encryption of PHI in transit and at rest, breach notification procedures, and business associate agreements with downstream vendors. HIPAA applies regardless of whether the data is from an FDA-regulated device or from Non-Device-MDDS — and applies regardless of whether the underlying software qualifies as MDDS.
Framework 3 — GDPR (EU data protection)
For medical device companies marketing in the European Union, GDPR applies to any personal data collected from EU residents. Health data is classified as a ‘special category of personal data’ under Article 9, requiring explicit consent or other specific legal bases for processing. GDPR’s territorial reach extends to non-EU companies that process EU residents’ data — meaning a US medical device startup with European customers must comply with GDPR even without an EU office. Requirements include data minimization, purpose limitation, data subject rights (access, rectification, erasure, portability), data protection impact assessments for high-risk processing, and breach notification within 72 hours.
Framework 4 — 21 CFR Part 11 (electronic records for FDA submissions)
21 CFR Part 11 governs the integrity and authenticity of electronic records and signatures used in FDA-regulated activities — including clinical investigations under Investigational Device Exemption (IDE) studies. The regulation applies to any electronic record that’s required to be maintained under FDA regulations or that’s submitted to FDA. Requirements include validation of computer systems; audit trails that record date/time and user identity for every record creation or change; signature controls; and procedures to ensure records remain trustworthy and retrievable throughout their retention period. For startups conducting IDE clinical studies, 21 CFR Part 11 compliance is not optional — and it applies to the data management infrastructure handling clinical investigation data, not just to the device itself.
Framework 5 — FDA cybersecurity requirements (Section 524B)
Section 524B of the Federal Food, Drug, and Cosmetic Act, added by the Consolidated Appropriations Act of 2023, established statutory cybersecurity requirements for cyber devices. Premarket submissions for cyber devices must include cybersecurity documentation: a Software Bill of Materials (SBOM), processes for monitoring and addressing post-market cybersecurity vulnerabilities, and design assurance documentation for cybersecurity controls. The requirements apply to medical devices with software, internet connectivity, or technological characteristics that could be vulnerable to cybersecurity threats. For medical device data management infrastructure, Section 524B affects how transmission security, authentication, and access controls are designed and documented.
Architecture for Medical Device Data Pipelines: The Five Layers
Medical device data pipelines have a common architectural pattern, regardless of the specific clinical domain. Understanding the five layers helps clarify which layer is subject to which regulatory framework, and where startup architecture decisions most affect downstream regulatory burden. The layers are not strict — many modern architectures collapse capture and transmission, or storage and conversion — but the conceptual separation clarifies what each layer is doing and how it should be designed.
Layer 1 — Capture (device to gateway)
Where physiological and telemetry data leaves the device and enters the connected ecosystem. Typically via BLE, Wi-Fi, cellular, or NFC to a smartphone, hub device, or directly to the cloud. This layer is where questions about data integrity begin: was the data captured accurately? Was the timestamp correct? Was the capture failure logged when transmission was unreliable? For investigational devices subject to 21 CFR Part 11, capture-layer audit trails are required and must be designed in from the start.
Layer 2 — Transmission (gateway to cloud)
Where data moves from the patient-side ecosystem to the manufacturer’s cloud infrastructure or a third-party platform. HTTPS/TLS encryption is table stakes; HIPAA and GDPR both require encryption in transit when handling personally identifiable health data. Transmission failures, retries, and queue management are also part of this layer — and the strategies chosen affect how data integrity is preserved during intermittent connectivity. Section 524B cybersecurity requirements affect the authentication and key management decisions at this layer.
Layer 3 — Storage (cloud or on-premise)
Where the data persists. Most modern medical device data architectures use cloud storage — AWS HealthLake, Google Cloud Healthcare API, Microsoft Azure for FHIR, or general-purpose cloud databases configured with HIPAA-compliant Business Associate Agreements. Storage decisions affect regulatory scope: storing PHI in a HIPAA-compliant region in a HIPAA-compliant configuration is required for US data; GDPR adds requirements about where EU residents’ data can be stored geographically. Encryption at rest is required under both frameworks; key management is where many startup architectures have the deepest implementation work to do.
Layer 4 — Conversion and integration (format transformation, EHR integration)
Where raw device data is transformed into formats consumable by clinical systems — HL7 v2 for legacy EHRs, FHIR for modern integrations, custom JSON or XML for proprietary platforms. This layer is where MDDS classification most clearly applies under FDA’s current guidance: format conversion according to a fixed specification is one of the four allowable MDDS functions. As long as the conversion is deterministic and doesn’t introduce analysis-driven outputs, this layer typically qualifies as Non-Device-MDDS and is not subject to FDA device regulation.
Layer 5 — Display and analysis
Where data is presented to clinicians, patients, or other users — dashboards, mobile apps, reports, exports, EHR-embedded views. Pure display layers (like Dexcom Clarity’s time-in-range reports or Tidepool’s data aggregation views) qualify as Non-Device-MDDS. But when analysis enters the display layer — predictive models showing the risk of hypoglycemia, automated pattern detection flagging clinically significant trends, and clinical decision support recommendations- the layer crosses from MDDS to SaMD classification. The line between display and analysis is where startup architectures most often blur, and where regulatory scope decisions get made implicitly rather than deliberately.
Common Medical Device Data Management Challenges Startups Face
The pattern of challenges in medical device data management is consistent across startups. Different products and different clinical domains, but the same four problem areas drive most of the architecture rework, regulatory remediation, and IDE-stage scrambling that companies experience late in development. Knowing the patterns in advance is the closest thing to a prevention strategy.
Challenge 1 — Regulatory ambiguity at the MDDS-SaMD boundary
The most common cause of architectural rework: building software that started as data display, then accumulated analysis features over time, and now sits ambiguously between MDDS and SaMD classification. The team thinks they’re building a Non-Device-MDDS data platform; the regulatory affairs team (or FDA) eventually identifies that the alerting features or pattern detection puts portions of the software into SaMD territory. The fix usually requires either pulling back the analysis features (which is often commercially undesirable) or accepting the SaMD regulatory burden retroactively. Both options have costs measured in months.
Challenge 2 — Multi-region compliance complexity
Startups building for the US market often design data infrastructure with HIPAA in mind, only to encounter GDPR requirements when EU expansion is added to the roadmap. The architectural implications can be substantial: data residency requirements that affect where servers can be located, data subject rights that affect how data deletion and portability work, and consent management workflows that don’t exist in HIPAA-only architectures. Retrofitting GDPR compliance onto a HIPAA-only architecture is meaningfully harder than designing for both frameworks from the start.
Challenge 3 — EHR integration complexity
Startups often assume EHR integration will be relatively straightforward through FHIR APIs, then encounter the reality of hospital IT environments: legacy HL7 v2 interfaces, inconsistent FHIR implementation across vendors (Epic, Cerner, Meditech), institution-specific data dictionaries, security review processes that can take months, and procurement cycles that put integration deployment behind sales-cycle timing. EHR integration is rarely the technical work people expect; it’s mostly process work.
Challenge 4 — Audit trail retrofit
21 CFR Part 11 audit trail requirements are easy to document on paper and hard to implement after the fact. Startups conducting IDE clinical studies sometimes discover, during study execution or FDA inspection preparation, that their data management infrastructure doesn’t produce the audit trails Part 11 requires — every data change recorded with date, time, and user identity; trustworthy and retrievable over retention periods; protected against modification. Retrofitting audit trails into a system that wasn’t designed for them is one of the more challenging remediation activities in medical device software.
How Medical Device Data Management Relates to MDDS Classification
Medical Device Data System (MDDS) classification is one slice of the broader medical device data management discipline — specifically, the slice that determines whether the data-handling layer of your software is subject to FDA device regulation at all. Under the 21st Century Cures Act of 2016 and FDA’s September 2019 implementation guidance, software functions that meet the MDDS criteria (transfer, storage, conversion, display of medical device data without analysis) are no longer FDA-regulated devices. This is the framework that allows substantial portions of modern connected device platforms to operate outside FDA device regulation.
But MDDS classification is not the same as the full medical device data management discipline. Even when your software qualifies as Non-Device-MDDS under FDA’s current guidance, HIPAA still applies, GDPR still applies (for EU data), 21 CFR Part 11 still applies (for clinical investigation data), and Section 524B cybersecurity requirements still apply (for cyber devices). The MDDS framework determines whether FDA device regulation applies; the other frameworks apply on their own terms regardless of MDDS status.
For startup medical device companies, the practical implication is that a thorough medical device data management strategy includes MDDS classification alongside compliance with HIPAA, GDPR, Part 11, and cybersecurity. Getting MDDS right narrows the regulatory scope of your platform; getting the other frameworks right keeps the narrowed scope defensible and compliant. The pages below walk through the MDDS-specific portions of the strategy in more detail.
What Medical Device Data Management Means for Startups Preparing for IDE Submission
For startup medical device companies preparing for an Investigational Device Exemption (IDE) submission, decisions about medical device data management affect the scope of the IDE submission in three concrete ways. First, the Software Description section of the IDE must describe what software is in scope as part of the investigational device — accurate MDDS classification narrows this scope to the software that is genuinely part of the device, excluding the Non-Device-MDDS data-handling layers. Second, the V&V plan must cover the in-scope software, but not the excluded layers — over-scoping creates months of unnecessary verification work; under-scoping creates audit risk. Third, the clinical data management infrastructure that captures the investigational data must be 21 CFR Part 11 compliant — this is non-negotiable for IDE studies and is the data management area most often retrofitted late.
The decision points where medical device data management most directly affects IDE submission preparation: choice of cloud platform (does it support the audit trails Part 11 requires?), authentication architecture (does it produce the user-identity records every data change must include?), data retention design (does it preserve trustworthy and retrievable records over the IDE study’s full retention period?), and EHR integration scope (which integrations are part of the investigational device, and which are part of the broader clinical workflow infrastructure?). Each of these decisions has implications that compound forward into IDE submission, premarket inspection, and post-approval operations.
Sequenex helps startup medical device companies make these decisions deliberately rather than discovering their implications during IDE submission preparation or FDA review. The work spans the boundary between engineering architecture and regulatory strategy — both disciplines need to inform the data management decisions because the consequences land on both sides. Engaging this work early, before significant engineering investment, is the lowest-cost way to keep the IDE submission’s scope and timeline under control.
Frequently Asked Questions About Medical Device Data Management
What is medical device data management?
Medical device data management is the discipline of capturing, transmitting, storing, converting, displaying, and integrating data from medical devices throughout their lifecycle. It combines engineering architecture (cloud infrastructure, secure pipelines, EHR integration) with regulatory compliance (MDDS, HIPAA, GDPR, 21 CFR Part 11, FDA cybersecurity) and clinical workflow integration. For medical device companies, getting it right early prevents architectural and regulatory rework later.
What are the regulatory requirements for medical device data?
Five frameworks typically apply, often simultaneously: FDA MDDS guidance (determines whether data-handling software is FDA-regulated as a device — post-Cures-Act, software-only MDDS is not), HIPAA (US data privacy and security for PHI), GDPR (EU data protection for personal data), 21 CFR Part 11 (electronic records for FDA-regulated activities including IDE studies), and Section 524B (FDA cybersecurity requirements for cyber devices). Each has distinct requirements; none substitute for the others.
Does HIPAA apply to medical device data?
Yes, when the device manufacturer is a covered entity or business associate of a covered entity (which most manufacturers are when they store, transmit, or process PHI on behalf of healthcare providers). HIPAA applies regardless of whether the data is from an FDA-regulated device or from Non-Device-MDDS software. It requires administrative, physical, and technical safeguards including access controls, audit logs, encryption of PHI in transit and at rest, and breach notification procedures.
What is the difference between medical device data management and EHR integration?
EHR integration is one layer of medical device data management — specifically, the conversion and integration layer that transforms device data into formats consumable by hospital EHR systems (typically HL7 v2 or FHIR). Medical device data management is broader, encompassing data capture from devices, secure transmission, cloud storage, format conversion, and display layers. EHR integration is necessary for clinical workflow, but it is only one piece of the full data management architecture.
Do I need to be HIPAA-compliant if my software is Non-Device-MDDS?
Yes, if your software handles Protected Health Information (PHI). Non-Device-MDDS status under FDA’s current guidance means your software is not subject to FDA device regulation — but it does not affect HIPAA, GDPR, or other data privacy frameworks. If your software stores, transmits, or processes PHI as a business associate of a covered entity (hospital, clinic, healthcare provider), HIPAA Privacy and Security Rules apply on their own terms regardless of MDDS status.
What are the cybersecurity requirements for medical device data?
For cyber devices subject to FDA review, Section 524B of the FD&C Act (added by the Consolidated Appropriations Act of 2023) requires cybersecurity documentation including Software Bill of Materials (SBOM), processes for monitoring post-market vulnerabilities, and design assurance documentation for cybersecurity controls. Beyond the FDA requirements, the HIPAA Security Rule requires technical safeguards (encryption, access controls, audit controls, integrity controls), and GDPR requires appropriate technical and organizational measures. Modern data management architectures need to satisfy all three.
Get Medical Device Data Management Right Before It Gets Expensive
Medical device data management decisions compound across IDE submission, regulatory review, and post-market operations. Sequenex helps startup medical device companies design data infrastructure deliberately, with engineering architecture and regulatory requirements informing each other from the start, rather than being discovered as constraints late in development.
